BOKU spin-off goes NASDAQ - and shines on Times Square!

What began in 2006 in a laboratory at the Department of Biotechnology at the University of Natural Resources and Applied Life Sciences in Vienna and opened its headquarters later in Cambridge was listed on one of the world’s largest stock exchanges at the beginning of this week: We are proud of F-star Therapeutics founders Florian Rüker, Gordana Wozniak-Knopp & colleagues!

F-star Therapeutics was founded in 2006 by the biotechnologists Florian Rüker, Gordana Wozniak-Knopp and colleagues. The company is based on the scientific invention to introduce antigen binding sites into non-conventional regions in antibody molecules. This method is used in the immunotherapy of various types of cancer. Currently, one such bispecific antibody is in clinical trials, two others are about to be tested. The company is growing steadily. Since November 23, F-star Therapeutics Inc. has been listed on the NASDAQ, as could be seen in New York's Times Square. BOKU is proud of this great success of its researchers!